Several terpene glycosides (e.g. mogroside V paenoiflorin geniposide rubusoside rebaudioside A steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds including but not limited to paclitaxel camptothecin curcumin tanshinone HA capsaicin cyclosporine erythromycin nystatin itraconazole celecoxib clofazimine digoxin oleandrin nifedipine and amiodarone. The use of the diterpene glycoside rubusoside and monoterpen...

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof.

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)) and also to processes for their preparation to their use as medicaments and to their use...

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine and/or nisoldipine and at least one angiotensin II antagonist characterized in that the active ingredient combination undergoes controlled (modified) release in the body and to processes for the production thereof to the use thereof as pharmaceuticals to the use thereof for the prophylaxis secondary prophylaxis and/or treatment of disorders and to the use thereof for manufactur...

The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)) and also to processes for their preparation to their use as medicaments and to their use...